Intraperitoneal and System Chemotherapy Versus XELOX as First-line Chemotherapy for mCRC
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
XELOX as first-line treatment regimen has limited efficacy against patients with metastatic
colorectal cancer (mCRC). Peritoneal metastasis is one of the most lethal factor for mCRC.
Intraperitoneal chemotherapy has became a widely accepted strategy in the treatment of
peritoneal dissemination. We hypothesized that combined multi-channel administration, such as
intraperitoneal chemotherapy, oral chemotherapy, and intravenous chemotherapy, can produce
better results than XELOX for first-line treatment for mCRC patients.
Phase:
Phase 2
Details
Lead Sponsor:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School